A joint venture between Vifor Pharma Group and Fresenius Medical Care has entered into a licencing agreement with Cara Therapeutics Inc of the US to develop and commercialise a drug for treating severe itching associated with chronic kidney disease.
The drug, CR845 (difelikefalin), is a peripherally acting kappa opioid receptor agonist in development for the treatment of pruritus and pain.